NCT06548412View on ClinicalTrials.gov

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2029

Conditions
Metastatic Biliary Tract Cancer
Interventions
DRUG

Gemcitabine

Given by IV

DRUG

Cisplatin

Given by IV

DRUG

Durvalumab

Given by IV

DRUG

CTX-009

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Compass Therapeutics, Inc
All Listed Sponsors
collaborator

Compass Therapeutics, Inc

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT06548412 - CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers | Biotech Hunter | Biotech Hunter